Skip to content Skip to footer

Pain Management & Beyond: Paul Howe from Protega Pharmaceuticals in a Stimulating Conversation with PharmaShots 

Shots: Abuse-deterrent products are prescription medications, primarily opioids and certain stimulants, designed to resist common methods of misuse, such as crushing, snorting, or injecting Protega Pharmaceuticals’ RoxyBond is the first and only FDA-approved, immediate-release abuse-deterrent opioid indicated for managing severe pain when alternative treatments are inadequate PharmaShots is pleased to feature Paul Howe, Chief Operations…

Read more

Strategies for enhancing comfort with clear aligners

Strategies for enhancing comfort with clear aligners

Clear aligners have revolutionized orthodontic care, offering a discreet and flexible alternative to traditional braces. However, managing discomfort during the adjustment phase is crucial for a successful treatment experience.The increasing popularity of clear aligners in orthodontic treatment is evident. This innovative approach offers aesthetic appeal and convenience, making it a preferred choice for many.…

Read more

Thoughtspot_Selina-Gran

Bridging the Gap Between Conventional and Integrative Medicine

Conventional medicine plays a crucial role in diagnosing, treating, and managing diseases through evidence-based interventions, including medications, surgeries, and other standardized treatments. However, there is a growing interest in integrative medicine, which combines conventional treatments with scientifically backed complementary therapies. This shift reflects a broader movement toward patient-centered, holistic healthcare that prioritizes both symptom relief…

Read more

Fermion Technology and Simcere Pharma Join Hands to Develop FZ002-037 for Pain Management

Shots:Fermion & Simcere Pharma have entered into an exclusive license and collaboration agreement to develop FZ002-037 for pain management As per the agreement, Simcere secures exclusive rights to develop & commercialize FZ002-037 across Greater China (Mainland China, Hong Kong, Macau & Taiwan) in exchange for an undisclosed upfront, milestones and sales-based tiered royalties…

Read more